For instance, BRAF/MEK inhibitors can mitigate the immunosuppressive milieu often associated with advanced melanoma, facilitating increased T cell infiltration and enhancing anti-tumor responses triggered by ICIs (173, 194). This evidence concerns the gene BRAF and melanoma.